Mankind Pharma Engages Kotak and IIFL for 3,000 Crore QIP to Fund BSV Acquisition - PUNE.NEWS
| 301230 Stock | 27.00 0.62 2.24% |
About 62% of PharmaResources' investor base is looking to short. The analysis of the overall investor sentiment regarding PharmaResources Co Ltd suggests that many traders are alarmed. The current market sentiment, together with PharmaResources' historical and current headlines, can help investors time the market. In addition, many technical investors use PharmaResources stock news signals to limit their universe of possible portfolio assets.
PharmaResources |
Mankind Pharma Engages Kotak and IIFL for 3,000 Crore QIP to Fund BSV Acquisition PUNE.NEWS
Read at news.google.com
 |
PharmaResources Fundamental Analysis
We analyze PharmaResources' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmaResources using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmaResources based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Last Dividend Paid
Last Dividend Paid Comparative Analysis
PharmaResources is currently under evaluation in last dividend paid category among its peers. Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
PharmaResources Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with PharmaResources stock to make a market-neutral strategy. Peer analysis of PharmaResources could also be used in its relative valuation, which is a method of valuing PharmaResources by comparing valuation metrics with similar companies.
Peers
PharmaResources Related Equities
| 601166 | Industrial Bank | 0.77 | ||||
| 601939 | China Construction | 0.47 | ||||
| 601988 | Bank of China | 0.38 | ||||
| 601857 | PetroChina | 0.36 | ||||
| 600036 | China Merchants | 0.29 | ||||
| 600938 | CNOOC | 0.04 | ||||
| 601288 | Agricultural Bank | 0.20 | ||||
| 601318 | Ping An | 0.21 | ||||
| 601398 | Industrial | 0.31 | ||||
| 600941 | China Mobile | 0.78 |
Complementary Tools for PharmaResources Stock analysis
When running PharmaResources' price analysis, check to measure PharmaResources' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaResources is operating at the current time. Most of PharmaResources' value examination focuses on studying past and present price action to predict the probability of PharmaResources' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaResources' price. Additionally, you may evaluate how the addition of PharmaResources to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |